UNSPSC 51143906: Indanorex

This classification denotes an anorexiant with the molecular formula C12H17NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 982LOO7DEE, chemically known as 1h-inden-2-ol, 2-(1-aminopropyl)-2,3-dihydro- but more generally known as indanorex, which bears US NIH Compound Identifier 65623. European Medicines Agency schedules Indanorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08168MIG.

UNSPSC 51143906 Indanorex, a Commodity code, covers pharmaceutical products and drug-related supplies that state and local governments procure for community health, emergency response, and public health programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Procurement vehicles include traditional IFBs with fixed two-year terms and optional renewals, RFIs for exploratory market intelligence prior to formal RFPs, and cooperative purchasing agreements administered through state procurement offices that serve multiple participating jurisdictions.

Activity under this code appears across Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment programs before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors on MMCAP awards must maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson as authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements.